National Institutes of Health (nih)

Clinical trial finds adding anti-clotting drugs to stroke care ineffective; medications did not improve patients’ outcomes, as indicated in The New England Journal of Medicine.

A $75.4 million grant-funded clinical trial at UCSF will test three drugs concurrently for progressive supranuclear palsy (PSP), aiming to slow its progression. The trial, emphasizing diverse enrollment and offering financial support, uses an innovative platform model to efficiently test new therapies, offering hope for PSP patients.

A $75.4 million NIH grant enables a UCSF-led clinical trial testing three drugs for progressive supranuclear palsy (PSP), aiming to slow its progression. The trial, involving up to 50 sites, uses a platform model to quickly identify effective therapies, prioritizing enrollment of diverse populations. CurePSP collaborates in recruitment, offering hope for patients and families.

The SPEC-AI Nigeria trial evaluated AI-guided ECG-based screening vs. clinical ECGs alone for identifying cardiomyopathy among pregnant/postpartum women in Nigeria, utilizing AI algorithms for ECG analysis. The trial, funded by Mayo Clinic and NIH, involved six hospitals, with participants aged 18-49, randomized to AI-guided screening or standard ECG, followed up to 12 months postpartum. The primary outcome was identification of LVEF < 50% by echocardiography, with secondary outcomes including AI model performance and effectiveness in identifying various LVEF levels.

Dr. Nick Dervisis and Dr. Shawna Klahn, experts in tumor ablation devices, join Purdue Veterinary Medicine's comparative oncology team, aiming to develop devices for clinical use and contribute to cancer research.

Purdue University's Pathway Ensemble Tool (PET) identifies dysfunctional biological pathways in cancer, leading to the discovery of an effective CDK9-inhibitor drug for bladder cancer, previously dismissed by traditional methods.

RWJBarnabas Health and Rutgers University collaborate to operate a world-class academic health system, focusing on life-changing research, clinical training, and high-quality health care. Their partnership aims to improve access to care, reduce health disparities, and drive innovations in health care in New Jersey. Through affiliations with Rutgers Health, they advance health science innovation, expand Centers of Excellence, increase accessibility to physicians, and dedicate resources to education and research. The collaboration also includes graduate medical education programs, advancing research and innovation, developing biomedical devices, and implementing a unified operating model with Epic for improved health care delivery.

An experimental malaria vaccine, tested in Malian adults, showed sustained protection against parasite infection and clinical malaria over two years without a booster dose. It also significantly protected women from malaria during pregnancy, suggesting potential for improved prevention strategies.

New imaging method detects Aspergillus fumigatus fungal infections sooner using radioactive cellobiose and PET scans, aiding early diagnosis and treatment response monitoring in immunocompromised patients.

FDA approves Zurnai (nalmefene hydrochloride) auto-injector for emergency treatment of opioid overdose, indicated for adults and patients aged 12+ with respiratory/CNS depression. Zurnai, containing 1.5 mg nalmefene per dose, is designed for immediate administration in opioid-present settings, not a substitute for emergency care. Contraindicated in hypersensitive patients. Purdue Pharma aims to provide Zurnai at no profit, addressing the opioid crisis.